These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Clinical features and laboratory findings of thrombotic thrombocytopenic purpura associated with ticlopidine]. Yagi H Rinsho Byori; 2005 Jul; 53(7):630-8. PubMed ID: 16104532 [TBL] [Abstract][Full Text] [Related]
3. Emerging roles of adjunct therapies in acquired thrombotic thrombocytopenia purpura. Racine-Brzostek SE; Shi PA Transfusion; 2019 Aug; 59(8):2496-2498. PubMed ID: 31283011 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in thrombotic thrombocytopenic purpura. Sadler JE; Moake JL; Miyata T; George JN Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study. Korkmaz S; Keklik M; Sivgin S; Yildirim R; Tombak A; Kaya ME; Acik DY; Esen R; Hacioglu SK; Sencan M; Kiki I; Tiftik EN; Kuku I; Okan V; Yilmaz M; Demir C; Sari I; Altuntas F; Unal A; Ilhan O Transfus Apher Sci; 2013 Jun; 48(3):353-8. PubMed ID: 23602056 [TBL] [Abstract][Full Text] [Related]
6. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura. Kubo M; Matsumoto M Int J Hematol; 2023 Mar; 117(3):331-340. PubMed ID: 36757521 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Matsumoto M; Miyakawa Y; Kokame K; Ueda Y; Wada H; Higasa S; Yagi H; Ogawa Y; Sakai K; Miyata T; Morishita E; Fujimura Y; Int J Hematol; 2023 Nov; 118(5):529-546. PubMed ID: 37689812 [TBL] [Abstract][Full Text] [Related]
8. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. Saha M; McDaniel JK; Zheng XL J Thromb Haemost; 2017 Oct; 15(10):1889-1900. PubMed ID: 28662310 [TBL] [Abstract][Full Text] [Related]
9. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Coppo P; Veyradier A Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954 [TBL] [Abstract][Full Text] [Related]
10. Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia. Martin IW; Katus MC; Martin CL; Szczepiorkowski ZM; Gorham JD; Dunbar NM J Clin Apher; 2016 Oct; 31(5):419-22. PubMed ID: 26332753 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation. Stefanello B; De Paula EV; Andrade Orsi F; Comenalli Marques JF; Gasparotto Roveri E; Pereira Colella M; Castro Ozelo M; Maria Annichino-Bizzacchi J; Addas-Carvalho M J Clin Apher; 2014 Dec; 29(6):311-5. PubMed ID: 24890787 [TBL] [Abstract][Full Text] [Related]
12. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK; N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070 [TBL] [Abstract][Full Text] [Related]